Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group.

We have analyzed factors influencing the outcome of 102 children with acute leukemia given a cord blood transplantation (CBT) and reported to the Eurocord Registry. Seventy patients with acute lymphoblastic and 32 with acute myeloid leukemia were given either a related (n = 42) or an unrelated (n = 60) CBT. Children given CBT during first or second complete remission were considered as belonging to the good-risk group (n = 66), whereas those who received a transplant in a more advanced stage of disease were assigned to the poor-risk group (n = 36). In the related group (RCBT), 12 of 42 patients received transplantation from an HLA-disparate donor, whereas in the unrelated group (UCBT) 54 of 60 received an HLA mismatched CBT. Kaplan-Meier estimates for neutrophil recovery at day 60 were 84% +/- 7% in RCBT and 79 +/- 6% in UCBT (P =.16). In multivariate analysis, the most important factor influencing neutrophil engraftment in UCBT was a nucleated cell dose infused greater than 3.7 x 10(7)/kg (P =.05, relative risk [RR] of 1.85, 95% confidence interval [CI]: 0.98-3.4). The incidence of grade II through IV acute graft-versus-host disease was 41% +/- 8% in the RCBT group and 37% +/- 6% in the UCBT group (P =.59). Kaplan-Meier estimates of 2-year event-free survival (EFS) after RCBT or UCBT were 39% +/- 8% and 30% +/- 7%, respectively (P =.19). In multivariate analysis, the most important factor influencing EFS was disease status at time of transplantation: good-risk patients had a 2-year EFS of 49% +/- 7% as compared to 8% +/- 5% in patients with more advanced disease (P =.0003, RR: 0.40, 95% CI: 0.24 to 0. 65). This was a consequence of both an increased 1-year transplant related mortality and a higher 2-year relapse rate in the poor-risk group (65% +/- 9% and 77% +/- 14%, respectively), as compared with good risk patients (34% +/- 6% and 31% +/- 9%, respectively). These data confirm that allogeneic CBT from either a related or an unrelated donor is a feasible procedure able to cure a significant proportion of children with acute leukemia, especially if transplanted in a favorable phase of disease.

[1]  J. Adamson,et al.  Outcomes among 562 recipients of placental-blood transplants from unrelated donors. , 1998, The New England journal of medicine.

[2]  Anajane G. Smith,et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.

[3]  Takato O. Yoshida,et al.  EFFECT OF MATCHING OF CLASS I HLA ALLELES ON CLINICAL OUTCOME AFTER TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS FROM AN UNRELATED DONOR , 1998 .

[4]  G. Janossy,et al.  Intracellular cytokine profile of cord and adult blood lymphocytes. , 1998, Blood.

[5]  D. Reen,et al.  Differential cytotoxicity of cord blood and bone marrow-derived natural killer cells. , 1998, Blood.

[6]  D. Srivastava,et al.  Outcomes of transplantation with matched-sibling and unrelateddonor bone marrow in children with leukaemia , 1997, The Lancet.

[7]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors , 1997 .

[8]  R Storb,et al.  Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. , 1997, Blood.

[9]  J. Wagner,et al.  Unrelated donor bone marrow transplantation for children with acute leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Gerna,et al.  High frequency of Epstein–Barr virus (EBV) lymphoblastoid cell line‐reactive lymphocytes in cord blood: evaluation of cytolytic activity and IL‐2 production , 1997, Clinical and experimental immunology.

[11]  C. Chastang,et al.  Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. , 1997, The New England journal of medicine.

[12]  G. Hale,et al.  Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission , 1996, British journal of haematology.

[13]  J. Wagner,et al.  Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. , 1996, Blood.

[14]  J. Kurtzberg,et al.  Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. , 1996, The New England journal of medicine.

[15]  A. Barrett,et al.  GRAFT‐VERSUS‐LEUKAEMIA: UNDERSTANDING AND USING THE ALLOIMMUNE RESPONSE TO TREAT HAEMATOLOGICAL MALIGNANCIES , 1996, British journal of haematology.

[16]  J. Adamson,et al.  Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Sullivan,et al.  Unrelated donor marrow transplantation in children. , 1995, Blood.

[18]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[19]  S. Mackinnon,et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.

[20]  J. Wagner,et al.  Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease , 1995, The Lancet.

[21]  N. Flomenberg,et al.  Characterization of the alloreactivity and anti-leukemia reactivity of cord blood mononuclear cells. , 1995, Bone marrow transplantation.

[22]  C. Herwartz,et al.  Leukemia-specific allogeneic donor T cells: quantification by limiting dilution assay. , 1995, Bone marrow transplantation.

[23]  J. Shuster,et al.  Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. , 1994, The New England journal of medicine.

[24]  D. Harris,et al.  Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease. , 1994, Bone marrow transplantation.

[25]  J. Hansen,et al.  Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. , 1993, The New England journal of medicine.

[26]  D. Deluca,et al.  Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Falkenburg,et al.  Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia , 1992, The Journal of experimental medicine.

[28]  R. Tattersall,et al.  Are diabetic pre-pregnancy clinics worth while? , 1992, The Lancet.

[29]  S. Richards,et al.  Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALLX , 1992, The Lancet.

[30]  S. Richards,et al.  Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: experience in MRC UKALL X. , 1992, Lancet.

[31]  H. Bolouri,et al.  Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease. , 1992, Annals of hematology.

[32]  A. B. Kay,et al.  Lymphocytes , 1991 .

[33]  R Hartmann,et al.  Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. , 1991, Blood.

[34]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[35]  J. Sosman,et al.  Specific recognition of human leukemic cells by allogeneic T cell lines. , 1989, Transplantation.

[36]  G. Santos.  Marrow transplantation in acute nonlymphocytic leukemia. , 1989, Blood.

[37]  James,et al.  Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. , 1989, Blood.

[38]  R. Maccario,et al.  T and NK Lymphocyte Subpopulations in the Neonate , 1987 .

[39]  H. Kolb.  Allogeneic bone marrow transplantation in leukemia. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[40]  R. Nuscher,et al.  Bone marrow transplantation. , 1977, The American journal of nursing.

[41]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[42]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[43]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.